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Background
Emerging epidemiologic studies describe an increased
prevalence of tumors in patients with non-oncogenic
chronic viral disease (e.g., non-AIDS-defining cancers
in HIV and non-hepatic cancers in HCV). However, there
is a lack of basic understanding by what mechanism infec-
tions result in increased unrelated cancer formation
(i.e., of cancers in tissues not associated with the infection),
and what role immunotherapy may have in the rescue of
immune responses under this condition. We hypothesized
that viral infections establish an immunological environ-
ment that leads to the preferential loss of anti-tumor
(i.e., anti-self antigen) CD8+ T cells, resulting in the inabil-
ity of the host to avert tumor growth, and further that
immunotherapy can reverse this detrimental loss.
Methods
We used a well-characterized mouse melanoma (B16-F10)
model and the well-accepted acute infection model of
influenza (PR/8). To follow anti-self and non-self CD8+
T cell responses, pmel (specific against melanocyte
gp10025-33; expressing Thy1.1) and OT-1 (specific against
non-self antigen OVA257-264; expressing Ly5.1) CD8+ T
cells were adoptively transferred into B6 (Thy1.1- Ly5.1-)
mice. B6 mice were infected with influenza (80,000 EID50)
via intranasal (i.n.) injection three days prior to or on the
same day as B16 melanoma challenge (120,000 cells
via intradermal injection). Some mice received PD-1 or
control IgG injection (125µg; i.p.) on days -6, -2, and 0.
Tumor area (width*length) was measured every two days
until host death and CD8+ T cells were detected by flow
cytometry.
Results
Influenza infection three days prior to tumor challenge
(but not concomitantly on day 0) significantly worsened
the natural anti-tumor response (specifically, decreased
survival from 35 days without to 23 days with infection;
P<0.01). Further, influenza infection resulted in the prefer-
ential loss of tumor antigen-specific (pmel) but not non-
self (OT-I) CD8+ T cells (up to 90%; P<0.001) from the
tumor and lymphoid tissues. Importantly, PD-1 blockage
reversed the effects of influenza infection on anti-tumor
responses and anti-tumor CD8+ T cell loss.
Conclusions
To our knowledge we are the first to report that anti-
tumor CD8+ T cell responses are preferentially lost in the
context of unrelated, non-oncogenic, viral infection. These
studies may answer the long-standing questions of why
certain individuals are more susceptible to tumor forma-
tion and less responsive to cancer therapies. Future efforts
will test whether these findings are universally applicable
to other infections and cancers and are expected to have
important clinical cancer immunotherapy implications.
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